VIGL: Vigil Neuroscience Inc. Analyst Median Target
The success of Vigil Neuroscience (VIGL) relies on the results of new drug trials and regulatory support, with the current indicator standing at 7.98. This price chart illustrates the price action of the company, which develops antibodies to combat brain degeneration. High brand authority among physicians and independence from market volatility transform this biopharmaceutical project into a resilient defensive asset for investors.
Analytical breakdowns for Vigil Neuroscience (VIGL)
- current price and projected stock value:
- market capitalization information:
- company book value details:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Vigil Neuroscience|VIGL - Long-Term Debt to Capital|Current Liabilities to Capital vigilneuro.com|VIGL - Company Total Debt|Debts to Book Capitalization Vigil Neuro|VIGL - Company Long-Term Debt|Company Short-Term Loans and Borrowings Vigil Neuroscience|Immediate Liquidity vigilneuro.com
- earnings and market multiples details:
VIGL - Net Income|Expected Profit Vigil Neuroscience|VIGL - P/E Multiple|Market Cap to Projected Earnings vigilneuro.com|VIGL - PEG Multiple|Enterprise Value to EBITDA Multiple Vigil Neuro|VIGL - Operating profit EBITDA|Net earnings per share for the last four quarters Vigil Neuroscience|VIGL - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months vigilneuro.com|VIGL - Net earnings per share growth this year|Expected earnings per share trend next year Vigil Neuroscience
Summary company analytics:VIGL Vigil Neuroscience Inc.
Stable funding for Vigil Neuroscience (VIGL) clinical trials through the support of pharma behemoths minimizes cash flow gaps, creating a reliable foundation for long-term capital. This analyst consensus chart aggregates investment bank price targets, filtering out market noise to determine the business's fundamental value, which confirms the company's resilience in the eyes of institutional investors.
Competitors of Vigil Neuroscience
Price Target Chart BIIB (biogen.com)|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|Analyst Median Target Regencell Bioscience Ltd (RGC)|Axsome Therapeutics Inc - Analyst Consensus Forecast|Analyst Target Range ACADIA Corp (ACAD)|Xenon Pharmaceuticals (XENE) - Price Target Chart|VKTX (vikingtherapeutics.com) - Price Target Chart|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Consensus Target PRTA|Price Target Chart ALEC|Analyst Consensus Forecast ANNX|Analyst Median Target omeros.com|Analyst Consensus Forecast NGNE (Neurogene Corp)|Analyst Target Range AC Immune Inc|Voyager Therapeutics - Analyst Consensus Forecast|Analyst Median Target neumoratx.com NMRA|Scilex (SCLX) - Price Target Chart|TVGN (Tevogen Bio Holdings Inc.) - Price Target Chart|Consensus Target ACOG|CGTX: Fair Value Consensus|Price Target Chart Inhibikase Therapeutics (IKT)|cassavasciences.com - Broker Consensus Forecast|Analyst Consensus Forecast ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Average Forecast Price|VTGN: Consensus Target|OVID - Analyst Consensus Forecast|Acumen Pharmaceuticals (ABOS) - Price Target Chart|cervomed.com - Fair Value Consensus|Price Target Chart Alterity Therapeutics Ltd.|Average Forecast Price Clene Nanomedicine CLNN|Price Target Chart PepGen Inc. (PEPG)|Analyst Median Target jupiterneurosciences.com|Analyst Consensus Forecast RLMD (Relmada Therapeutics)|ANVS - Consensus Target|Grace Tx - Analyst Consensus Forecast|Analyst Median Target Firefly Neuroscience, Inc. AIFF|KLTO: Analyst Consensus Forecast|Average Forecast Price NeuroSense Therapeutics Ltd. (NRSN)|Price Target Chart Reviva Pharmaceuticals|Broker Consensus Forecast MTVA (MetaVia, Inc.)|Analyst Consensus Forecast NRXS|Consensus Target heliusmedical.com HSDT|Analyst Consensus Forecast PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Average Forecast Price|NERV: Consensus Target|ATHA: Price Target Chart|ADXN: Analyst Consensus Forecast|ALZN - Analyst Median Target|CYCN (Cyclerion Therapeutics Inc.) - Analyst Consensus Forecast|PTIX - Analyst Target Range|Price Target Chart Pasithea Therapeutics (KTTA)|Price Target Chart CRGT (cortigent.com)|Price Target Chart Avenue Therapeutics, Inc. ATXI|BCLI: Broker Consensus Forecast|Cara Therapeutics, Inc - Analyst Consensus Forecast|Average Forecast Price Chromocell|ELYM (eliemtx.com) - Consensus Target|Intra-Cellular Therapies, Inc. (ITCI) - Analyst Consensus Forecast|Price Target Chart Longboard Pharmaceuticals, Inc.|MRNS: Fair Value Consensus|Price Target Chart NKGen (NKGN)|NRBO - Average Forecast Price|Sage Therapeutics, Inc. - Consensus Target|synaptogen.com - Price Target Chart|Trevena - Analyst Consensus Forecast|Analyst Median Target Anew Medical Inc. WENA|CERE: Analyst Consensus Forecast
